NICE TAs

24/06/2026

TA1171: Seladelpar for previously treated primary biliary cholangitis

18/06/2026

TA1168: Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)

18/06/2026

TAA1167: Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

17/06/2026

TA1166: Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

16/06/2026

TA1165: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer

11/06/2026

TA1164: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

TA1163: Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)

04/06/2026

TA1162: Nusinersen and risdiplam for treating spinal muscular atrophy

03/06/2026

TA1161: Sotatercept for treating pulmonary arterial hypertension

03/06/2026

TA1159: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment

03/06/2026

TA1160: Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

29/05/2026

TA1158: Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

29/05/2026

TA1157: Givinostat for treating Duchenne muscular dystrophy in people 6 years and over

21/05/2026

TA1156: Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

20/05/2026

TA1155: Rozanolixizumab for treating antibody-positive generalised myasthenia gravis

07/05/2026

TA1152: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

07/05/2026

TA1154: Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)

07/05/2026

TA1153: Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

06/05/2026

TA1151: Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)

30/04/2026

TA1149: Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma